Mice were sensitized with 100 µg of Grade V chicken OVA (Sigma-Aldrich, St. Louis MO) mixed with 2 mg aluminum hydroxide in saline by intraperitoneal (i.p.) injection twice, once a week as previously described [16 (link), 17 (link)]. Mice were then challenged with aerosolized 3% OVA for 30 min once for the acute model or 3 times per week for 4 weeks for the chronic model. Administration i.p. of S-NACH (water soluble) or vehicle (saline) was done 30 min after the OVA challenge. Mice were sacrificed 48 h later for bronchoalveolar lavage (BAL) or lung fixation and processing. Some mice were subjected to AHR measurements 24 h after the OVA challenge as described [16 (link), 17 (link)].
Chicken ova grade 5
Manufactured by Merck Group
Sourced in United States
Chicken OVA (Grade V) is a laboratory product provided by Merck Group. It is a powder form of chicken egg albumin, commonly known as ovalbumin, which is the main protein found in egg whites. This product is suitable for various applications in research and testing environments.
Automatically generated - may contain errors
9 protocols using chicken ova grade 5
1
Murine Allergic Asthma Induction and Treatment
2
OVA-Induced and HDM-Challenged Murine Asthma Model
3
Chronic Mouse Model of hRV-Induced Asthma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mouse models of asthma exacerbations caused by hRV infection were established as described elsewhere, with some modification (39 (link)). The experimental WT BL/6 and IDO KO mice were sensitized with 100 μg of chicken OVA (Grade V; Sigma-Aldrich) absorbed to 2 mg of aluminum hydroxide (alum; Sigma-Aldrich) in a volume of 200 μl of PBS via intraperitoneal (i.p.) injection. After 10 days, the mice were challenged with 50 μg of OVA (Sigma-Aldrich) in 30 μl of PBS (controls received PBS alone) on 3 consecutive days via the intranasal (i.n.) route under light anesthesia using isoflurane. For asthma exacerbation by hRV infection, the third OVA solution included hRV (1×107 TCID50). UV-inactivated hRV (1,200 mJ/cm2, 30 min) was used as the negative control for hRV. To establish a chronic model of hRV-induced asthma exacerbation, BL/6 and IDO KO mice were sensitized twice with 50 μg of OVA in 2 mg of alum on days 0 and 7 through i.p. injection. Ten days later, the mice were challenged with either 50 μg of OVA or PBS for 3 consecutive days via the i.n. route. For the hRV-induced asthma exacerbation in the chronic model, the third OVA solution included hRV (1.0×107 TCID50), and that 3-consecutive-days challenge was repeated 5 times every 7 days.
4
Murine Model of Allergic Airway Inflammation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The protocol was performed according to the report as previously described.14 Briefly, BALB/c mice were intraperitoneally injected with 2 μg of α‐GalCer in 0.5% polysorbate‐20 or the same volume of 0.5% polysorbate‐20 in PBS. After 9 days, mice were immunized by intraperitoneal injection with 50 μg of chicken OVA (grade V; Sigma, St. Louis, MO) adsorbed to 2 mg of aluminium hydroxide (Thermo Scientific Pierce, Rockford, IL). Another 9 days later, mice were challenged with intranasal administration of 50 μg of OVA in PBS on days 18, 19 and 20. Airway hyperresponsiveness was measured 24 hours after the final challenge, and then bronchoalveolar lavage fluid (BALF) and lungs were obtained for further analysis.
5
OVA-Induced Asthma Model in C57BL/6 Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Six-week-old female C57BL/6 mice were purchased and housed in a specific pathogen-free facility in the Experimental Animals Center of Guangzhou Institutes of Biomedicine and Health (GIBH). The protocols of animal experiments were approved by the Institutional Animal Care and Use Committee of GIBH (Permit No. 2013026).
The asthma model was established as described previously [8 (link), 16 (link)]. In brief, mice were sensitized by three intraperitoneal (I.P.) injections at weekly intervals with 50 μg of chicken OVA (Grade V, Sigma-Aldrich, St. Louis, MO) in 2 mg of alum (Sigma-Aldrich, St. Louis, MO). Three weeks after the final sensitization, the mice were challenged with aerosolized OVA (2% in saline) for 40 min for three consecutive days. One day after the last challenge, the mice were evaluated for AHR and then sacrificed.
The asthma model was established as described previously [8 (link), 16 (link)]. In brief, mice were sensitized by three intraperitoneal (I.P.) injections at weekly intervals with 50 μg of chicken OVA (Grade V, Sigma-Aldrich, St. Louis, MO) in 2 mg of alum (Sigma-Aldrich, St. Louis, MO). Three weeks after the final sensitization, the mice were challenged with aerosolized OVA (2% in saline) for 40 min for three consecutive days. One day after the last challenge, the mice were evaluated for AHR and then sacrificed.
6
Ovalbumin-Induced Murine Asthma Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female mice (8‐week‐old) were sensitized with an intraperitoneal (i.p.) injection of 10 μg of chicken OVA (Grade V, Sigma‐Aldrich, St. Louis, MO, USA) and 0.3 mg of Al(OH)3 (SERVA Electrophoresis, Heidelberg, Germany) on Days 1 and 14 and then 12‐week‐old mice were challenged with aerosolized 1% OVA for 30 min on Days 26, 27, and 28. Mice were assessed for airway hyperresponsiveness (AHR) followed by bronchoalveolar lavage (BAL) on Day 30, as previously described (Kibe et al. 2003 ). Experimental protocols are described in Figure 1 .
7
Allergen Sensitization and Challenge Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The offspring were sensitized and challenged with allergens as previously described.29 (link) Offspring were sensitized by intraperitoneal injection (IP) with 10 μg chicken OVA (Grade V, Sigma Aldrich Co., St. Louis, MO, USA) emulsified in 2 mg of alum (Shanghai No. 4 Reagent & H.V. Chemical Industries Ltd., Shanghai, China) in a total volume of 100 μL of 0.9% sterile saline at 8 weeks of age (Day 0) and boosted 14 days later (Day 14). Non-sensitized mice received phosphate buffered saline (PBS) in the same volume. For the OVA challenge, mice were placed in a plastic box (50 × 30×40 cm3) and inhaled 1% OVA in a saline (10 mg/mL) aerosol delivered using an ultrasonic nebulizer (PARI BOY, Starnberg, Germany) for 30 min on 5 successive days from Day 21 to Day 25. Each group consisted of 7 to 9 mice.
8
Murine Model of Allergic Airway Inflammation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
WT BALB/c mice were sensitized intraperitoneally on days 0 and 14 of an airway challenge experiment with 20 µg chicken OVA (grade V; Sigma-Aldrich; Merck KgaA, Darmstadt, Germany) emulsified in 2 mg aluminum hydroxide (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in 200 µl phosphate-buffered saline (PBS). Intranasal OVA challenges (100 µg in 50 µl PBS) were administered on days 25, 26 and 27. Age- and sex-matched control mice (6 mice per group) from the same batch of wild-type (WT) female BALB/c mice were simultaneously treated with PBS alone. Mice were sacrificed 24 h after the final OVA challenge with an intraperitoneal injection of sodium pentobarbitone (100 µg/kg; Mintal; Mitsubishi Tanabe Pharma, Osaka, Japan) and their lungs were harvested for analysis.
9
OVA-Induced Allergic Airway Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Wildtype and NO-GC1 KO Mice (7–8 weeks old) were sensitized and challenged with chicken OVA grade V (Sigma, St. Louis, MO). Briefly, the mice were sensitized by an intraperitoneal injection (100 μl) of 20 μg OVA emulsified in 2 mg Imject Alum (Al [OH]3/Mg [OH]2; Pierce, Rockford, IL) on days 0, 14 and 21. Subsequently, mice were challenged with an OVA aerosol every week on two consecutive days over a period of eight weeks. The OVA aerosol was generated using a PARI-Boy aerosol generator (PARI, Starnberg, Germany) from a 1% (wt/vol) OVA solution in saline for 30 min.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!